All In Biotech

NDA 208143 · Bracco

Varibar Honey

Barium Sulfate · Oral · Radiographic Contrast Agent

Last checked: Nov 20, 2026Latest source record: Mar 10, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Jan 15, 2016

Approved uses

7

Original approval plus efficacy supplements

Registered trials

25

4 Phase 3, 5 recruiting

FAERS reports

353

212 serious, 31 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 15, 2026.

VARIBAR THIN HONEY is indicated for modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. VARIBAR THIN HONEY is a radiopaque contrast agent indicated for use in modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients ( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

8 products under this application
  • VARIBAR HONEY · BARIUM SULFATE 40% · SUSPENSION, ORAL · Prescription
  • TAGITOL V · BARIUM SULFATE 40% · SUSPENSION, ORAL · Prescription
  • LIQUID E-Z-PAQUE · BARIUM SULFATE 60% · SUSPENSION, ORAL · Prescription
  • READI-CAT 2 · BARIUM SULFATE 2% · SUSPENSION, ORAL · Prescription
  • ENTERO VU 24% · BARIUM SULFATE 24% · SUSPENSION, ORAL · Prescription
  • VARIBAR THIN HONEY · BARIUM SULFATE 40% · SUSPENSION, ORAL · Prescription
  • VARIBAR NECTAR · BARIUM SULFATE 40% · SUSPENSION, ORAL · Prescription
  • READI-CAT 2 SMOOTHIE · BARIUM SULFATE 2% · SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Barium" as an intervention, any sponsor and status, largest first.

All 25 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • urticaria27
  • diarrhoea26
  • pruritus19
  • acute kidney injury18
  • dyspnoea18
  • renal failure18
  • no adverse event16
  • vomiting16
  • chronic kidney disease15
  • rash15
  • abdominal pain13
  • nausea13

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20063
20073
200821
20096
201010
201113
201212
201317
201413
20159
201620
201728
201827
201927
202018
202127
202232
202323
202412
202517
202613

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 728 on PubMed

Sponsor: Bracco · Also marketed as Tagitol V, Liquid E-Z-Paque, Readi-Cat 2, Entero Vu 24%, Varibar Thin Honey

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.